Posted by Michael Wonder on 20 Sep 2021
Melinta Therapeutics announces two key milestones expanding reimbursement and access for Kimyrsa (oritavancin)
20 September 2021 - Kimyrsa receives product specific J code and transitional pass through status from CMS.
Melinta Therapeutics today announced two important milestones for Kimyrsa (oritavancin), a lipoglycopeptide antibiotic that was launched in July.
The Centers for Medicare & Medicaid Services has issued a permanent product-specific J code (J2406) for Kimyrsa Injection effective 1 October 2021.
CMS has also granted transitional pass-through status for Kimyrsa in the hospital outpatient department setting of care.
